HanYShaHZhouL, et al.A study of calcineurin inhibitors in comparison with intravenous cyclophosphamide for initial induction treatment of lupus nephritis class III, IV, V in Chinese children. Lupus2025; 0(0): 1–11.
2.
TanakaHAizawaTWatanabeS, et al.Efficacy of mizoribine-tacrolimus-based induction therapy for pediatric lupus nephritis. Lupus2014; 23(8): 813–818.
3.
MaoYYinLHuangH, et al.Addition of cyclosporine/tacrolimus for pediatric relapsed lupus nephritis during mycophenolate mofetil maintenance therapy. J Int Med Res2019; 47(1): 105–113.
4.
TakeuchiTWakasugiNHashidaT, et al.Long-term safety and effectiveness of tacrolimus in patients with lupus nephritis in Japan: 10-year analysis of the real-world TRUST study. J Rheumatol2024; 51: 613–621.
5.
Van SchaikMBredewoldOWPriesterM, et al.Long-term renal and cardiovascular risks of tacrolimus in patients with lupus nephritis. Nephrol Dial Transplant2024; 39(12): 2048–2057.
6.
KhatriSBajeerIAAzizM, et al.Insights into pediatric lupus nephritis: clinical features and short-term outcomes from a single center retrospective study. BMC Nephrol2025; 26: 145.
7.
ParodisICetrezNPalazzoL, et al.Lupus nephritis trials network (LNTN) repeat kidney biopsy-based definitions of treatment response: a systematic literature review-based proposal. Autoimmun Rev2025; 24: 103810.
8.
De MutiisCWenderferSEOrjuelaA, et al.Defining renal remission in an international cohort of 248 children and adolescents with lupus nephritis. Rheumatology2022; 61(6): 2563–2571.
9.
ContrerasGLenzOPardoV, et al.Outcomes in African Americans and Hispanics with lupus nephritis. Kidney Int2006; 69(10): 1846–1851.
